Invitae Corporation

Equities

NVTA.Q

US46185L1035

Biotechnology & Medical Research

End-of-day quote OTC Markets Other stock markets 06:00:00 2024-04-17 pm EDT			5-day change	1st Jan Change
0.0034 ^USD	+25.93%		+1,033.33%	-99.46%

Apr. 11	Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance	CI
Mar. 12	Invitae Launches Update to Invitae Generation: Clinical Variant Modeling Improves Variant Classification	CI

Invitae Corporation Announces Resignation of Katherine A. Stueland as its Chief Commercial Officer

June 11, 2021 at 08:03 am EDT

Invitae Corporation announced that on June 9, 2021, Katherine A. Stueland, the company's Chief Commercial Officer, notified the Company that effective June 18, 2021, she will be stepping down from her role to accept a CEO position at another company.

Latest news about Invitae Corporation

Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance	Apr. 11	CI
Invitae Launches Update to Invitae Generation: Clinical Variant Modeling Improves Variant Classification	Mar. 12	CI
Earnings Flash (NVTA) INVITAE CORPORATION Posts Q4 Revenue $127.8M	Mar. 06	MT
Invitae Corporation Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2023	Mar. 06	CI
Bidding Procedure Approved for Invitae Corporation	Feb. 15	CI
Motion for Joint Administration Approved for Invitae Corporation	Feb. 15	CI
Invitae gets court approval for five-month bankruptcy sale	Feb. 15	RE
Global markets live: Airbnb, Sony, Uber, Lyft, Nvidia...	Feb. 14
Genetic test maker Invitae files for bankruptcy protection in US	Feb. 13	RE
Motion for Asset Sale Filed by Invitae Corporation	Feb. 13	CI
Invitae Corporation Lists Estimated Assets In The Range Of $500 Mln -$1 Bln - Court Filing	Feb. 13	RE
INVITAE CORPORATION LISTS ESTIMATED LIABILITIES IN THE RANGE OF…	Feb. 13	RE
Genetic test maker Invitae files for voluntary Chapter 11 protection	Feb. 13	RE
Motion for Joint Administration Filed by Invitae Corporation	Feb. 12	CI
Invitae Corporation Filed for Bankruptcy	Feb. 12	CI
Invitae Corporation(OTCPK:NVTA) dropped from S&P Global BMI Index	Feb. 08	CI
Invitae Corporation(OTCPK:NVTA) dropped from S&P TMI Index	Feb. 08	CI
Global markets live: BP, Palantir, Infineon, Toyota, UBS...	Feb. 06
Invitae Corporation May File for Bankruptcy	Feb. 06	CI
Sector Update: Health Care Stocks Rise Late Afternoon	Feb. 05	MT
Sector Update: Health Care Stocks Advance Monday Afternoon	Feb. 05	MT
Invitae to File for Bankruptcy in Coming Weeks	Feb. 05	MT
Medical test maker Invitae prepares for bankruptcy - WSJ	Feb. 05	RE
Invitae Collaborates With BridgeBio Pharma for Rare Disease Therapeutics	Jan. 30	MT
Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics	Jan. 30	CI

Chart Invitae Corporation

Duration

Period

More charts

Company Profile

Invitae Corporation is a medical genetics company. The Company is engaged in delivering genetic testing services, digital health solutions, and health data services that support a lifetime of patient care and improved outcomes. It offers genetic testing across multiple clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases and pharmacogenomics. It applies proprietary design, process automation, robotics and bioinformatics software solutions to expand the use and impact of genetic information in sample processing and complex variant interpretation, allowing medical interpretation at scale. The Company also utilizes digital health solutions to improve ease-of-use and to deliver actionable information about risk, prevention, treatment, and monitoring. The Company has served over 3.6 million patients, and over 2.2 million of those patients have made their information available for data sharing.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

	1st Jan change	Capi.
INVITAE CORPORATION	-99.46%	974K
EXACT SCIENCES CORPORATION	-17.60%	11.52B
IOVANCE BIOTHERAPEUTICS, INC.	+39.11%	3.27B
BGI GENOMICS CO., LTD.	-20.67%	2.02B
VERACYTE, INC.	-29.30%	1.44B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+11.45%	1.01B
SEEGENE, INC.	-6.33%	719M
CAREDX, INC	-30.75%	418M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-51.02%	339M
CURIOX BIOSYSTEMS CO., LTD	-2.58%	284M

Bio Diagnostics & Testing